CME Presentations

Mitochondrial Diseases


Presentations


Speakers


CME Information

Recognizing, Diagnosing, and Treating Mitochondrial Diseases: Understanding the Patient Journey – An Interactive Discussion Between Patients/Caregivers and HCPs

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with United Mitochondrial Disease Foundation (UMFD) and The National Organization for Rare Disorders (NORD).

ACKNOWLEDGEMENT

Supported by an educational grant from Zogenix.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Friday, October 8, 2021, at 10:00 AM EST

Enduring Material

October 8, 2021 - October 8, 2022.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Identify the key clinical findings and presenting symptoms for suspicion of mitochondrial diseases, such as TK2 deficiency
  • Summarize the disease burden and key clinical manifestations of mitochondrial diseases across the spectrum of disease severity and age (i.e., early onset vs late onset)
  • Utilize genetic testing as part of a diagnostic approach to differentiate mitochondrial diseases from conditions such as spinal muscular atrophy and Pompe disease
  • Explain how treatment with dC/dT has impacted the lives of patients/caregivers

TARGET AUDIENCE

The intended audience for this activity neuromuscular specialists and neurologists in specialized centers, community neuromuscular specialists and neurologists, pediatric neurologists, pediatricians, primary care providers, pulmonologists, gastroenterologists, advanced practice providers (NPs, PAs), physical therapists/occupational therapists, nutritionists, genetic counselors, and geneticists.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.



The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Michio Hirano, MD
Lucy G. Moses Professor of Neurology
Chief, Neuromuscular Medicine Division
Director, H. Houston Merritt Neuromuscular Research Center
Columbia University Irving Medical Center
Vagelos College of Physicians and Surgeons
Royalty: Modis Therapeutics following Columbia University policies
Receipt of lntellectual Property Rights/Patent Holder: Co-inventor of a Columbia University patent on deoxynucleoside therapy (deoxythymidine and deoxycytidine) for mitochondrial DNA depletion syndrome. That patent is licensed to Modis Therapeutics (a subsidiary of Zogenix)
Consulting Fees (e.g., advisory boards): Modis Therapeutics (a subsidiary of Zogenix), Entrada Therapeutics, and Neurovive.
Contracted Research: Stealth Therapeutic and Entrada Therapeutics
Colleen C Muraresku, MS, LCGC
Certified Genetic Counselor
Program Director of Mitochondrial Medicine at Children’s Hospital of Philadelphia, PA
Nothing to disclose
Jean Flickinger, PT, DPT, PCS
Physical Therapist
Neuromuscular Program at Children's Hospital of Philadelphia
Consulting Fees (e.g., advisory boards): 2020 USMA Pompe Disease Advisory Board
Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): MDA, Sanofi Genzyme
Contracted Research: Astellas, IMEL Therapeutics and Khondrion

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Support@NeuroSeriesLive.com.